Otros idiomas iBio, Inc. Börse Stuttgart

Acciones

0JV0

US4510337086

Mercado cerrado - Börse Stuttgart Otros sitios de cotización 20:33:21 28/11/2023			Varia. Cinco días.	Varia. 1 de enero.
0,186 ^EUR	-31,11 %		-19,13 %	-.--%

28/05	IBIO, INC. : Chardan Research mantiene una recomendación de compra.	ZM
13/05	IBio, Inc. informa de los resultados del tercer trimestre y de los nueve meses finalizados el 31 de marzo de 2024	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

IBIO, INC. : Chardan Research réitère son opinion positive sur le titre	28/05
IBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	13/05
Ibio, Inc. Appoints Dr. Martin Brenner, to the Board of Directors, Effective June 1, 2024	13/05
Top Premarket Gainers	28/03
Top Midday Gainers	27/03
Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	27/03
Transcript : IBio, Inc. - Special Call	27/03
US Futures Trend Higher Wednesday Pre-Bell as Investors Eye Impending Economic, Inflation Data Readings	27/03
Top Premarket Gainers	27/03
IBio, Inc. and AstralBio, Inc. Announce Transformative AI Drug Discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases	27/03
Otsuka Pharmaceutical Co., Ltd. completed the acquisition of Preclinical PD-1 Agonist Antibody Program of iBio, Inc..	25/02
IBio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	09/02
Top Midday Decliners	05/12
Top Premarket Decliners	05/12
Reverse Split: 1 for 20	29/11	FA
IBio, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	14/11
IBio, Inc. Announces Expansion of its AI-Powered Technology Stack with Launch of ShieldTx	01/11
IBio, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	27/09/23
IBio Unit, Woodforest National Bank Amend Credit Agreement	21/09/23
IBio, Inc. Reports Triple Milestone in Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development	14/08/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas iBio, Inc. Börse Stuttgart

Acciones

0JV0

US4510337086

Otros idiomas

Filtros